Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1108-1114

  Nix, David E ^a,b,c   Wilton, John H ^a   Hyatt, Judith ^a   Thomas, Jennifer ^a   Strenkoski Nix, Laura C ^a   Forrest, Alan ^a,b   Schentag, Jerome J ^a,b  

^a Millard Fillmore Gates Circle Hospital   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; OFLOXACIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MIXTURE; ENTEROBACTER CLOACAE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PRURITUS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RASH; SEROCONVERSION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0030902086     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1108     Document Type: Article

References (29)

1. Barriere, S. L., E. Ely, J. E. Kapusnik, and J. G. Gambertoglio. 1983. Analysis of a new method for assessing activity ot combination of antimicrobials: area under the bactericidal activity curve. J. Antimicrob. Chemother. 16:49-59.
2. Craig, W. 1993. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. Eur. J. Clin. Microbiol. Infect. Dis. 12(Suppl. 1):S6-8.
3. Craig, W. A., and S. C. Ebert. 1992. Continuous infusion of β-lactam antibiotics. Antimicrob. Agents Chemother. 36:2577-2583.
4. Craig, W. A., and B. Suh. 1991. Protein binding and the antimicrobial effects: methods for the determination of protein binding, p. 367-390. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Williams & Wilkins, Baltimore, Md.
5. D'Argenio, D. Z., and A. Schumitzy. 1992. Adapt II (version 3): mathematical software for pharmacokinetic-pharmacodynamic systems analysis. Biomedical Simulation Resource, University of Southern California, Los Angeles, Calif.
6. Eliopoulos, G. M., and R. C. Moellering, Jr. 1991. Antimicrobial combinations, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Williams & Wilkins, Baltimore, Md.
7. Flaherty, J. P., D. Waitley, B. Edin, et al. 1989. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am. J. Med. 87(Suppl. 5A):278S-282S.
8. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
9. Goss, T. F., A. Forrest, D. E. Nix, et al. 1994. Mathematical examination of dual individualization principles (II): the rate of bacterial eradication at the same area under the inhibitory curve is more rapid than for cefmenoxime. Ann. Pharmacother. 28:863-868.
10. Guay, D., K. Tack, and S. Flor. 1991. Safety and pharmacokmetics of single dose intravenous ofloxacin in healthy volunteers. Int. J. Clin. Pharmacol. Res. 11:203-209.
11. Guay, D. R., J. A. Opsahl, F. G. McMahon, R. Vargas, G. R. Matzke, and S. Flor. 1992. Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 36:308-312.
12. Hilf, M., V. L. Yu, J. Sharp, J. J. Zuravleff, J. A. Korvick, and R. R. Muder. 1989. Antibiotic therapy of Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am. J. Med 87:540-546.
13. Hyatt, D. E., T. R. F. Rogers, D. M. McCarthy, and D. S. Samson. 1991. A randomized trial of ciprofloxacin plus azlocillin versus netilmicin plus azlocillin for the empirical treatment of fever in neutropenic patients. J. Antimicrob. Chemother. 28:24-26.
14. Jenkins, S. G., and J. W. Lewis. 1995. Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens. Infection 23:154-162.
15. Jones, R. N. 1989. A review of cephalosporin metabolism: a lesson to be learned for future chemotherapy. Diagn. Microbiol. Infect. Dis. 12:25-31.
16. Jones, R. N., and A. L. Barry. 1987. Antimicrobial activity of ceftriaxone, cefotaxime, desacetyl-cefotaxime, and cefotaxime-desacetyl-cefotaxime in the presence of human serum. Antimicrob. Agents Chemother. 31:818-820.
17. Kelsey, S. M., M. E. Wood, E. Shaw, G. C. Jenkins, and A. C. Newland. 1990. A comparative study of intravenous ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin for the empirical treatment of fever in neutropenic patients. J. Antimicrob. Chemother. 25:149-157.
18. Leggett, J. E., and W. A. Craig. 1989. Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli. Antimicrob. Agents Chemother. 33:35-40.
19. Leggett, J. E., S. A. Wolz, and W. A. Craig. 1989. Use of serum ultrafiltrate in the serum dilution test. J. Infect. Dis. 160:616-623.
20. Lode, H., G. Höffken, P. Oschewski, B. Sievers, A. Kirch, K. Borner, and P. Koeppe. 1987. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob. Agents Chemother. 31:1338-1342.
21. Maiche, A. G., and L. Teerenhovi. 1991. Empiric treatment of serious infections in patients with cancer. Randomized comparison of two combinations. Infection 19(Suppl. 6):326-329.
22. Okazakio, O., C. Kojima, H. Hakusui, and M. Nakashima. 1991. Enantio-selective disposition of ofloxacin in humans. Antimicrob. Agents Chemother. 35:2106-2109.
23. Patel, K. B., D. P. Nicolau, C. H. Nightingale, and R. Quintiliani. 1995. Pharmacokinetics of cefotaxime in healthy volunteers and patients. Diagn. Microbiol. Infect. Dis. 22:49-55.
24. Philpott-Howard, J. N., K. F. Barker, J. J. Wade, R. S. Kaczmarski, J. C. Smedley, and G. J. Mufti. 1990. Randomized multicentre study of ciprofloxacin and azlocillin versus gentamicin and azlocillin in the treatment of febrile neutropenic patients. J. Antimicrob. Chemother. 26(Suppl. F):89-99.
25. Samuelsson, J., P. Nilsson, A. Wahlin, R. Lemer, I. Winqvist, and J. Palmblad. 1992. A pilot study of piperacillin and ciprofloxacin as initial therapy for fever in severely neutropenic leukemia patients. Scand. J. Infect. Dis. 24:267-275.
26. Schentag, J. J., D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. Drug Intell. Clin. Pharrn. 25:1050-1057.
27. Stratton, C. W., M. P. Weinstein, and L. B. Reller. 1982. Correlation of serum bactericidal activity with antimicrobial agent level and minimum inhibitory concentration. J. Infect. Dis. 145:160-168.
28. Vallée, F., and M. LeBel. 1991. Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime. Antimicrob. Agents Chemother. 35:2057-2064.
29. Young, L. S. 1982. Combination or single drug therapy for gram-negative sepsis. In J. S. Remington and M. V. Swartz (ed.), Current clinical topics in infectious diseases. McGraw-Hill, New York, N.Y.